Daljit Singh Aurora Sells $432K of Neumora Therapeutics Inc (NMRA) — SEC Form 4, Aug 19, 2026
Open-Market Net Sale · SEC Form 4
−$431,674
Equity position changed by -24.7%
Equity Position
104K sh
137,786 → 103,766
Equity Change
-24.7%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Daljit Singh Aurora CIK 0001793971 |
Officer
|
Daljit Singh Aurora at Neumora Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$1,030,583
More from this insider at Neumora Therapeutics Inc
| 2026-08-21 | Sell | -$269,967 | View |
| 2026-02-19 | Sell | -$21,917 | View |
| 2026-01-09 | Award | — | View |
| 2025-11-13 | Sell | -$307,025 | View |
| 2025-05-30 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-17 | M - Exercise | 40,890 A | $0.72 | +$29,441 | 123,660 | Direct |
| Common Stock | 2026-08-17 | M - Exercise | 15,355 A | $0.72 | +$11,056 | 139,015 | Direct |
| Common Stock | 2026-08-17 | M - Exercise | 1,424 A | $0.72 | +$1,025 | 140,439 | Direct |
| Common Stock | 2026-08-17 | M - Exercise | 1 A | $0.72 | +$1 | 140,440 | Direct |
| Common StockF3 | 2026-08-17 | M - Exercise | 25,279 A | $0.72 | +$18,201 | 25,279 | Indirect See footnote |
| Common StockF3 | 2026-08-17 | M - Exercise | 29,737 A | $0.72 | +$21,411 | 55,016 | Indirect See footnote |
| Common StockF1 | 2026-08-17 | S - Sale | 57,670 D | $1.51 | -$86,822 | 82,770 | Direct |
| Common StockF2 | 2026-08-17 | S - Sale | 34,020 D | $1.49 | -$50,530 | 48,750 | Direct |
| Common StockF4F3 | 2026-08-17 | S - Sale | 55,016 D | $1.50 | -$82,783 | 0 | Indirect See footnote |
| Common Stock | 2026-08-18 | M - Exercise | 34,162 A | $0.72 | +$24,597 | 82,912 | Direct |
| Common StockF3 | 2026-08-18 | M - Exercise | 34,987 A | $0.72 | +$25,191 | 34,987 | Indirect See footnote |
| Common StockF9 | 2026-08-18 | S - Sale | 34,162 D | $1.58 | -$54,137 | 48,750 | Direct |
| Common StockF10F3 | 2026-08-18 | S - Sale | 34,987 D | $1.59 | -$55,486 | 0 | Indirect See footnote |
| Common Stock | 2026-08-19 | M - Exercise | 13,268 A | $0.72 | +$9,553 | 62,018 | Direct |
| Common Stock | 2026-08-19 | M - Exercise | 17,732 A | $0.72 | +$12,767 | 79,750 | Direct |
| Common StockF3 | 2026-08-19 | M - Exercise | 30,918 A | $0.72 | +$22,261 | 30,918 | Indirect See footnote |
| Common StockF11 | 2026-08-19 | S - Sale | 31,000 D | $1.65 | -$51,029 | 48,750 | Direct |
| Common StockF12F3 | 2026-08-19 | S - Sale | 30,918 D | $1.65 | -$50,888 | 0 | Indirect See footnote |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $0.72 | 2026-08-17 | M - Exercise | 40,890 D | $0.00 | 2031-09-20 | 40,890 Common Stock | Direct |
| Stock Option (Right to Buy)F6 | $0.72 | 2026-08-17 | M - Exercise | 15,355 D | $0.00 | 2033-01-19 | 15,355 Common Stock | Direct |
| Stock Option (Right to Buy)F7 | $0.72 | 2026-08-17 | M - Exercise | 1,424 D | $0.00 | 2033-06-23 | 1,424 Common Stock | Direct |
| Stock Option (Right to Buy)F8 | $0.72 | 2026-08-17 | M - Exercise | 1 D | $0.00 | 2035-02-13 | 1 Common Stock | Direct |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-17 | M - Exercise | 25,279 D | $0.00 | 2033-01-19 | 25,279 Common Stock | Indirect See footnote |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-17 | M - Exercise | 29,737 D | $0.00 | 2033-06-23 | 29,737 Common Stock | Indirect See footnote |
| Stock Option (Right to Buy)F7 | $0.72 | 2026-08-18 | M - Exercise | 34,162 D | $0.00 | 2033-06-23 | 34,162 Common Stock | Direct |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-18 | M - Exercise | 34,987 D | $0.00 | 2033-01-19 | 34,987 Common Stock | Indirect See footnote |
| Stock Option (Right to Buy)F7 | $0.72 | 2026-08-19 | M - Exercise | 13,268 D | $0.00 | 2033-06-23 | 13,268 Common Stock | Direct |
| Stock Option (Right to Buy)F13 | $0.72 | 2026-08-19 | M - Exercise | 17,732 D | $0.00 | 2034-02-14 | 17,732 Common Stock | Direct |
| Stock Option (Right to Buy)F5F3 | $0.72 | 2026-08-19 | M - Exercise | 30,918 D | $0.00 | 2033-01-19 | 30,918 Common Stock | Indirect See footnote |
Footnotes (13)
- F1
- This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F2
- This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F3
- Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Show more
- F4
- This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F5
- The stock option is fully vested and exercisable. Show more
- F6
- 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
- F7
- 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
- F8
- 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
- F9
- This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F10
- This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F11
- This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F12
- This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F13
- 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
Remarks
Title: Chief Operating and Development Officer
Show moreRelated filings at Neumora Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
113
institutional managers reporting a position
Largest by reported value
- Siren, L.L.C. $14.4M
- Black Rock, Inc. $13.2M
- Softbank Group Corp. $10.4M
5%+ Holders · 13D/G
2 filers
-
Paul L Berns 5.1%
Other insiders at Neumora Therapeutics Inc
GET /v1/forms/4/0001610717-26-000362
API docs
View Original SEC Filing